Regeneron Replaces Annual Equity with One-Time 10-Year Performance Awards for CEO and CSO
REGN sits 39% above its 52-week low of $541.
Summary
Regeneron granted its CEO and CSO one-time 10-year performance share awards worth up to 5.6 million shares combined, replacing all annual equity grants until 2036 and tied to ambitious new-product revenue and TSR goals.
Key Events · Executive and Board Changes · REGN
-
One-Time 10-Year PSU Awards Granted
Effective September 24, 2026, CEO Leonard Schleifer received up to 2,700,000 PSUs and CSO George Yancopoulos up to 2,900,000 PSUs, replacing all annual equity awards until 2036.
-
Revenue Hurdles Set Payout Scale
No revenue-based PSUs are earned below $10 billion in new product annual revenue; 250,000 PSUs vest at $10 billion, 900,000 at $18 billion, and 1,800,000 at $30 billion, with linear interpolation between levels.
-
Relative TSR Modifier of ±20%
Earned PSUs adjust up or down 20% based on Regeneron's total shareholder return versus the Nasdaq Biotechnology Index over the 10-year period, with no upward adjustment if absolute TSR is negative.
-
Mandatory Holding Period to 2036
All delivered shares are non-transferable until February 2036, with a 20% holdback on early deliveries pending final relative TSR certification.
Analysis · REGN · Life Sciences
In a decisive move, Regeneron has replaced all annual equity awards for its two co-founders with a single front-loaded performance award covering 2026–2035. CEO Leonard Schleifer can earn up to 2.7 million shares and CSO George Yancopoulos up to 2.9 million shares, but only if the company generates up to $30 billion in new product annual revenue — roughly double 2025 total revenue — and beats the Nasdaq Biotech Index on total shareholder return. The awards carry a mandatory holding period until February 2036 and a 20% holdback pending the relative TSR adjustment. This structure locks in the co-founders for a decade and ties their pay directly to pipeline and commercial execution, while removing annual equity grants as a recurring compensation lever.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1609 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, REGN was trading at $753.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.1B. The 52-week trading range was $541.00 to $859.34. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.